A Multicenter, Open-label Study to Determine the Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Myeloma response
randomization to progression
No
Robert Knight, MD
Study Director
Celgene Corporation
United States: Food and Drug Administration
CC-5013-MM-014
NCT00065351
July 2003
March 2007
Name | Location |
---|---|
Mayo Clinic | Rochester, Minnesota 55905 |
Fred Hutchinson Cancer Research Center | Seattle, Washington 98109 |
Swedish Cancer Institute | Seattle, Washington 98104 |
Dana-Farber Cancer Institute | Boston, Massachusetts 02115 |
Mayo Clinic | Jacksonville, Florida 32224 |
Wilshire Oncology Medical Group, Inc. | Rancho Cucamonga, California 91730 |
Western Pennsylvania Cancer Institute | Pittsburgh, Pennsylvania 15224 |
Nevada Cancer Center | Las Vegas, Nevada 89109 |
Alta Bates Comprehensive Cancer Center | Berkeley, California 94704 |
Massachusetts General Hospital | Boston, Massachusetts 02114-2617 |
St. Vincent's Comprehensive Cancer Center | New York, New York 10011 |
Midwest Cancer Research Group | Skokie, Illinois 60077 |
Mayo Clinic | Scottsdale, Arizona |
Cancer Care Associates | Fresno, California 93720 |
Northwestern University Med Ctr | Chicago, Illinois 60611-2927 |
Center for Cancer and Blood Disorders | Bethesda, Maryland 20817 |
Palo Verde Hematology Oncology | Glendale, Arizona 85304 |
Providence St. Joseph Medical Center/Cancer Center | Burbank, California 91505 |
Institute for Myeloma and Bone | Los Angeles, California 90067 |
Northwest Georgia Oncology Centers | Marietta, Georgia 30060 |
Atlanta Cancer Care-Roswell | Roswell, Georgia 30076 |
University of Maryland Medical Center | Baltimore, Maryland 21201-1595 |
University of Massachusetts | Worcester, Massachusetts 01655 |
SUNY Health Science Center at Brooklyn | Brooklyn, New York 11203 |
Carolina Hematology-Oncology Associates | Charlotte, North Carolina 28203 |
Cleveland Clinic Myeloma Program Hematology & Medical Oncology /R35 | Cleveland, Ohio 44195 |